Tbh no, especially given AZ make up the majority of UK vaccinations,
Is it suggestive, yes but we really need more data that as far as I’m aware we don’t have.
My major issues with the change in the Pfizer dosage by the UK (against manufacturers recommendations) wasn’t ao much that it happened, given B1117 was rife it was a calculated gamble. However it wasn’t accompanied by a rigorous data collection exercise of precisely how it impacted outcomes (measuring patients antibody levels, detailed symptom tracking compared to the 3 week gap, death/hospitalization rates for vaccine delayed recipients etc) and that everyone involved wasn’t aware of the greater risk with informed consent.
The UK winged it with Pfizer and as you say it appears to have worked out but honestly it was a pretty half assed approach that makes it hard for any other nation to replicate it in good conscience.
In contrast the delay with AZ was supported by the initial trial results, admittedly those being due to a serendipitous mess up of their trial.